IVIg is recommended for patients with encephalitis and flaccid paralysis, may be considered in brainstem encephalitis. IVIg is also recommended when there are ANS dysregulations and may be considered when there is cardiopulmonary failure and IVIg hasn't been given yet. IVIg is not indicated for patients with aseptic meningitis as these usually have a good prognosis (26).
can be considered in patients with drowsiness and frequent myoclonic jerks, or acute paralysis, respiratory rate >30-40 times/minutes at rest, heart rate >140-150 and signs of peripheral perfusion insufficiency such as sweating, cold extremities, or skin color change.
Malaysia:
In Malaysia there are no national guidelines. The Sibu hospital in Sarawak uses a clinical management protocol that describes a staged approach similar to the stages used in the Cambodia and Taiwan (51), with encephalomyelitis as stage 2 and autonomic and cardiopulmonary dysfunction as stage 3. IVIg use is described for stage 2 and 3 but only after lumbar puncture (showing pleiocytosis) and consultation with a pediatrician, and is said to be less effective in stage 3. After 2011 the WHO guidelines have been adopted.
China:
The 2011 consensus document from China CDC indication describes the following indications for IVIg: symptoms of hand-food-mouth disease or herpangina, or untypical symptoms with consistent exposure history of enterovirus infection, and one of the following:
• myoclonic jerks AND tachycardia (heart rate >150/minute)
• acute paralysis • signs and symptoms after 24h to 48h
• time to resolution of physiologic derangements (tachycardia, tachypnea, fever)
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• duration of hospitalization
• need for and duration of mechanical ventilation
• need for rescue therapy (milrinone, CRRT/ECMO, inotropic support, other rescue therapy)
• neurologic sequelae at discharge and 6mo follow-up, including neurodevelopmental assessment using Bayley score
• MRI abnormalities at discharge
• subgroup analysis of patients who did and did not receive phenobarbital before randomization (part of guidelines in Vietnam)
• EV or EV71 qPCR positivity in rectal/NP swabs on day 1-2-3-4-5 or until discharge and after 2 weeks at follow-up (all qPCRs will be performed at a single location)
• acute, before and after study drug dosage 1 and 2 and convalescent serum (after 2 weeks at follow-up)
• CRP and procalcitonin levels at randomization
• cardiac troponin I or T at randomization
• natriuretic peptide β at randomization
• cytokines (G-CSF, IL-5) levels at randomization and after 1 st and 2 nd study drug
• cost-effectiveness
Subsidiary studies
• subgenotyping, whole genome sequencing of viruses
• qPCR positivity for enteroviruses / EV71 of blood day 1/ CSF (if collected)
• host genetics
• cardiac ultrasound at day 1, 2, 3, discharge
• IVIg neutralization titers of different IVIg brands
